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The preparation of two types of imidazole derivatives bearing a hydrazide group 
was achieved by treatment of the corresponding esters with NH2NH2·H2O in MeOH at 
room temperature. In the case of 4-(ethoxycarbonyl)imidazole 3-oxides 3, hydrazides of 
type 1 were formed with retention of the N-oxide structure (Scheme 1). Interestingly, 
due to a strong hydrogen bonding, no deoxygenation of the N→O function could be 
achieved even by treatment of 3 with Raney-nickel. The second type, 2-[(imidazol-2-
yl)sulfanyl]acetohydrazides 2, was obtained from 1H-imidazole-2(3H)-thiones 4 in two 
steps via S-alkylation with methyl bromoacetate followed by treatment with 
NH2NH2·H2O (Scheme 2). An imidazole 7, containing both types of hydrazide groups, 
was prepared analogously from ethyl 2,3-dihydro-2-thioxoimidazole-4-carboxylate 4d 
(Scheme 4). Both types of hydrazides, 1 and 2, were transformed successfully into the 
corresponding acylhydrazones 8 and 9, respectively (Scheme 5). Furthermore, it has 
been shown that hydrazides of type 1 are useful starting materials for the synthesis of 
1,2,4-triazole-3-thiones 11 and 1,3,4-thiadiazole-2-amines 12, bearing an imidazole 3-
oxide residue (Scheme 7).  
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1. Introduction. – In a series of our recent publications, various syntheses of 
imidazole derivatives including optically active products were reported [1]. It is well 
documented that some imidazole derivatives such as imidazole N-oxides [2], imidazole-
2-thiones [3] or 2-sulfanylimidazoles [4] show diverse biological activities. On the other 
hand, imidazole N-oxides were used for the preparation of more complex N-heterocles 
via Pd-catalyzed direct arylation [5], and in the case of optically active derivatives, they 
were applied as promising ligands for asymmetric allylation of aromatic aldehydes [6]. 
Acyl hydrazides were widely reported as biologically active compounds, and 
similar properties were shown for their derivatives, e.g., hydrazones, semicarbazones, 
and thiosemicarbazones [7]. Furthermore, acid hydrazides are privileged starting 
materials for the preparation of various heterocycles like 1,2,4-triazoles, 1,3,4-
thiadiazoles, 1,3,4-oxadiazoles, etc. [8]. 
The goal of the present study was the synthesis of acid hydrazides containing 
differently substituted imidazole moieties starting with corresponding esters described 
in our recent publications. For the first time, acid hydrazides derived from 3-
oxidoimidazole carboxylic acids and the influence of the oxido function on the 
reactivity of the hydrazide unit and vice versa will be reported. In addition, the synthesis 
of corresponding hydrazones as representative derivatives is presented. 
 
2. Results and Discussion. – For the synthesis of imidazole containing acid 
hydrazides of types 1 and 2, the typical protocol based on the treatment of the 
corresponding ethyl carboxylates with NH2NH2·H2O [9] was applied, and the expected 
products were obtained in high yields. 
The imidazole N-oxides 3 bearing the ester group at C(4) were easily available 
from the reaction of 2-hydroxyimino-3-oxobutanoate with the corresponding primary 
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amine and CH2O [1g][10]. Treatment with NH2NH2·H2O in MeOH at room temperature 
led to the products 1a–1c, which were obtained as crystalline materials in good yields 
(Scheme 1). Their structures were determined on the basis of their spectroscopic data. 
The presence of the N-oxido function was evidenced by the diagnostic high field shifted 
H–C(2) signal at 8.60 – 8.37 ppm.  
 
Scheme 1 
 
Finally, the structure of 1b was established by X-ray crystallography (Figure). 
The N(4)–H group forms bifurcated H-bonds.  One interaction is an intramolecular H-
bond with the adjacent oxide O(1)-atom to form a loop, which can be described by a 
graph set motif [12] of S(6).  The second interaction is an intermolecular H-bond with 
the oxide O-atom of a neighboring molecule.  This interaction links pairs of molecules 
related by a centre of inversion into dimers and the motif thus formed can be described 
by a graph set motif of R2,2(12).  The same two molecules are also linked by a H-bond 
between the NH2 group and the oxide O-atom.  The motif in this case is R2,2(14).  The 
other H-atom of the NH2 group forms an intermolecular H-bond with the hydrazide 
O(2)-atom of a different neighboring molecule.  This interaction links these molecules 
into centrosymmetric dimers and can be described by a graph set motif of R2,2(10). The 
combination of all intermolecular H-bonds links the molecules into two-dimensional 
layer networks which lie parallel to the (001) plane.  The Ph rings from adjacent layers 
interdigitate. 
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Figure. ORTEP Plot [11] of the molecular structure of 1b (with 50% probability 
ellipsoids; arbitrary numbering of the atoms) 
 
Interestingly, in contrast to the ester 3a, the attempted ‘sulfur-transfer reaction’ 
[1a] aimed at obtaining of the corresponding imidazole-2-thione from the acid 
hydrazide 1a was unsuccessful. Moreover, the typical thermal isomerization of 2-
unsubstituted imidazole N-oxide derivatives to the corresponding imidazol-2-ones was 
not achieved even after heating of 1a in boiling toluene. Finally, the attempted 
deoxygenation with Raney-Ni, which was performed smoothly in many other cases of 
imidazole N-oxides [1c–1e], did not afford the expected products. All these facts point 
out that the presence of the hydrazide function strongly influences the reactivity of the 
oxido function, most likely as a result of a strong intramolecular H-bond between the 
hydrazide N–H and the oxide O-atom. 
The second type of acid hydrazides 2 presented in this study was obtained via S-
alkylation of imidazole-2-thiones 4 with methyl bromoacetate and subsequent 
conversion of the ester function (Scheme 2). A convenient access to the differently 
substituted starting materials 4 is the so-called ‘sulfur-transfer reaction’ [1a][1e], in 
which the 2-unsubstituted imidazole N-oxide is treated with a cycloaliphatic thioketone. 
The crystalline hydrazides 2a–2c were obtained in good yields. 
 
Scheme 2 
 
Another method used for the incorporation of an ester group into the side chain 
of imidazoles consists of the condensation of α-hydroxyimino ketones with CH2O and 
an appropriate α-amino acid ester [1e]. In that case, the ester group is placed in the  
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α-position of the side chain at N(1). Unexpectedly, by treatment with NH2NH2·H2O, 
even under very mild conditions, the imidazole N-oxides 5a–5b were converted into the 
α-(imidazol-1-yl)carboxylic acids 6a–6b in nearly quantitative yields (Scheme 3). The 
preservation of the N-oxide function was confirmed by the 1H-NMR spectra, which 
showed the typical absorption for H–C(2) at 8.13 for 2a and 8.36 ppm for 2b, 
respectively. 
 
Scheme 3 
 
Starting with 2-thioxoimidazole-4-carboxylate 4d, which was obtained in 
analogy to the corresponding N-Ph amide [1g] by the ‘sulfur-transfer reaction’ with 3b, 
subsequent alkylation with methyl bromoacetate and treatment with two equivalents of 
NH2NH2·H2O led to the bis-hydrazide 7 (Scheme 4). The latter represents an example in 
which the structure elements of type 1 and type 2 are combined.  
 
Scheme 4 
 
Both types of easily available acid hydrazides, 1 and 2, are attractive starting 
materials for further syntheses involving the hydrazide group. In the present study, they 
were used for the formation of hydrazones with various aldehydes and ketones 3). In the 
case of acid hydrazides 1b and 1c, the reactions with benzaldehyde, adamantan-2-one, 
and cyclohexanone, respectively, in MeOH occurred smoothly at room temperature and 
yielded the expected hydrazones 8a–8f in high yields. The analogous reactions with 
                                                          
3) For some recent articles on synthesis and biological interest of acylhydrazones see 
[7a][8a][13]. 
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acetophenone required acid catalysis (AcOH in EtOH, reflux) to give 8e and 8f (Scheme 
5), whereas with benzophenone no hydrazone was obtained. 
A series of hydrazones of type 9 derived from hydrazides 2a–2c was prepared by 
using some of aromatic aldehydes and cyclohexanone. The reactions were carried out in 
boiling EtOH in the presence of catalytic amounts of AcOH, and in all cases the 
products were isolated as crystalline materials (Scheme 5). 
 
Scheme 5 
 
In contrast to hydazide 1a, which did not undergo the ‘sulfur transfer reaction’ 
upon treatment with 2,2,4,4-tetramethylcyclobutane-1,3-dithione, the analogous 
reaction with hydrazide hydrazone 8c afforded, after 24 h at room temperature in 
CH2Cl2, the expected imidazol-2-thione derivative 4e in 88% yield (Scheme 6). It is 
worth mentioning that corresponding N-Me and N-Ph-substituted 3-oxidoimidazole-4 
carboxamides react under similar conditions [1g], whereas the transformation of 4-
methyl- and 4-phenylimidazole-3-oxides is complete within ca. 30 min. This result 
confirms the importance of the H-bonding between the amide and hydrazide function 
and the N→O group for the tuning of the reactivity of imidazole N-oxide as a 1,3-dipol 
[1a].  
 
Scheme 6 
 
The reaction of acid hydrazides with isothiocyanates is a typical procedure 
applied for the preparation of 1,3,4-thiadiazoles or 1,2,4-triazole-3-thiones [14]. The 
two-steep reactions led initially to thiosemicarbazides, which subsequently undergo 
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cyclocondensation under acidic or basic reaction conditions. Using these methods, 
hydrazide 1b was smoothly converted into triazole thione 11 by heating of 
thiosemicarbazide 10 in aqueous NaOH solution, whereas after stirring of a solution of 
1b in conc. H2SO4 at room temperature, thiadiazole 12 was obtained in high yield 
(Scheme 7). 
 
Scheme 7 
 
3. Conclusions. – The presented results show that differently substituted 
imidazole N-oxides containing an ester group can be easily transformed into the 
corresponding acid hydrazides without loss of the N-oxide function. To the best of our 
knowledge, there are no such examples of azaheterocyclic N-oxides reported to date. 
The presence of the hydrazide function and the N-oxide group offer a unique 
opportunity for their exploration in the synthesis of more complex heterocycles, which 
are potentially useful building blocks for the preparation of products with biological 
activity. Some imidazole derivatives containing hydrazide [15] or hydrazone moieties 
[16] were reported as potential pharmaceuticals, a fact, which is also reflected by 
several patents, e.g. [17]. 
In addition, imidazole N-oxides can be transformed into imidazole-2-thiones, 
which may be used for syntheses of another class of acid hydrazides containing the 
imidazole unit. These products can also be considered as potentially useful starting 
materials for the preparation of diverse polyheterocycles. 
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Experimental Part 
 
1. General. M.p.: Melt-Temp. II (Aldrich); uncorrected. IR Spectra: NEXUS FT-
IR spectrophotometer; in KBr; absorptions in cm–1. 1H- and 13C{1H}-NMR Spectra: 
Bruker Avance III 600 using solvent signal as reference; δ in ppm; coupling constants J 
in Hz. Assignments of signals in 13C-NMR spectra were made on the basis of HMQC 
experiments. EI-HR-MS: Bruker Esquire LC spectrometer, ESI-HR-MS: Finnigan 
MAT-95 instrument. Optical rotations were determined on a PERKIN-ELMER 241 MC 
polarimeter for λ = 589 nm. 
2. Starting Materials. All solvents are commercially available and were used as 
received. Imidazole N-Oxides 3a,b,c and 5a,b, and 1H-imidazole-2-thiones 4a–c were 
prepared following known procedures [1a][1e]. 2,2,4,4-Tetramethylcyclobutane-1,3-
dithione was prepared by thionation of 2,2,4,4-tetramethylcyclobutane-1,3-dione using 
P2S5 as a thionating reagent [18].  
3. General Procedure for the Synthesis of Hydrazides 1. To a soln. of freshly 
prepared imidazole N-oxide ester 3 (10 mmol) in MeOH (5 ml), was added NH2NH2·H2O 
(20 mmol). The mixture was stirred for 16 h at r.t., the solvent was evaporated under 
vacuum, and the residue was crystallized from MeOH.  
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 1,5-Dimethyl-3-oxido-1H-imidazole-4-carboxyhydrazide (1a). Yield: 1.02 g 
(65%). Colorless crystals. M.p. 242–246º (decomp., MeOH). IR (KBr): 3309s, 3261s 
(N–H), 1648vs (C=O), 1601vs, 1530m, 603m. 1H-NMR ((D6)DMSO): 11.58 (br. s, 
NH); 8.37 (s, H–C(2)); 4.49 (br. s, NH2); 3.54 (s, MeN); 2.48 (s, Me). 13C-NMR 
((D6)DMSO): 159.3 (C=O); 133.3, 120.7 (C(4), C(5)); 126.6 (C(2)); 32.2 (MeN); 9.3 
(Me). HR-ESI-MS: 171.0874 ([M+H]+, C6H11N4O2; calc. 171.0876).  
 1-Benzyl-5-methyl-3-oxido-1H-imidazole-4-carboxyhydrazide (1b): Yield: 
1.353 g (55%). Colorless crystals. M.p. 228–230º (decomp., MeOH). IR (KBr): 3296vs 
(NH), 1661vs (C=O), 1604vs, 1579m, 977m. 1H-NMR ((D6)DMSO): 11.57 (br. s, NH); 
8.60 (s, H–C(2)); 7.40–7.21 (m, 5 arom. H); 5.21 (s, CH2); 4.51 (br. s, NH2); 2.42 (s, 
Me). 13C-NMR ((D6)DMSO): 159.2 (C=O); 136.0, 121.3 (C(4), C(5)); 130.0 (1 arom. 
C); 129.4, 128.6, 127.6 (5 arom. CH); 126.6 (C(2)); 48.6 (CH2); 9.6 (Me). HR-ESI-MS: 
247.1191 ([M+H]+, C12H15N4O2; calc. 247.1190).  
 1-Cyclohexyl-5-methyl-3-oxido-1H-imidazole-4-carboxyhydrazide (1c): 
Yield: 1.428 g (60%). Colorless crystals. M.p. 170–172º (MeOH). IR (KBr): 3305s, 
3271s (NH), 1655vs (C=O), 1600vs, 1544m, 1416m, 1281m. 1H-NMR ((D6)DMSO): 
11.63 (br. s, NH); 8.58 (s, H–C(2)); 4.49 (br. s, NH2); 4.09–4.00 (m, CH); 2.55 (s, Me); 
1.96–1.76 (m, 4 cyclohexyl H); 1.70–1.57 (m, 3 cyclohexyl H); 1.46–1.35 (m, 2 
cyclohexyl H); 1.22–1.11 (m, 1 cyclohexyl H). 13C-NMR ((D6)DMSO): 159.4 (C=O); 
129.2, 120.3 (C(4), C(5)); 124.2 (C(2)); 55.0 (CH); 33.0, 25.4, 25.0 (5 cyclohexyl CH2); 
9.33 (Me). HR-EI-MS: 239.1494 ([M+H]+, C11H19N4O2; calc. 239.1502).  
 Treatment of ethyl α-(imidazol-1-yl)carboxylates 5 with NH2NH2·H2O 
following the same procedure led to the corresponding carboxylic acids 6. 
 (S)-2-(4,5-Dimethyl-3-oxido-1H-imidazol-1-yl)propanoic Acid (6a). Yield: 
1.656 g (90%). Yellowish oil. [α]D20 = +74 (c = 1, MeOH). IR (film): 1683vs (C=O), 
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1633m, 1568m, 1410m, 1337m. 1H-NMR (CD3OD): 8.18 (s, H–C(2')); 4.63 (q, J = 7.2, 
CH); 2.16, 2.15 (2s, 2 Me); 1.68 (d, J = 7.2, Me). 13C-NMR (CD3OD): 174.8 (C=O); 
124.8, 122.7 (C(4’), C(5’)); 124.3 (C(2’)); 57.0 (CH); 17.2 (Me); 7.3, 5.6 (2 imidazole 
Me). HR-EI-MS: 185.0921 ([M+H]+, C8H13N2O3; calc. 185.0927).  
 (S)-2-(4,5-Dimethyl-3-oxido-1H-imidazol-1-yl)-3-methylbutanoic Acid (6b). 
Yield: 1.844 g (87%). Yellowish oil. [α]D20 = +34 (c = 1, MeOH).  IR (film): 1671vs (br. 
C=O), 1633m, 1558m, 1411m, 1333m. 1H-NMR (CD3OD): 8.36 (s, H–C(2')); 4.21 (d, J 
= 10.6, CHN); 2.42–2.35 (m, CH); 2.22, 2.15 (2s, 2 Me); 1.03 (d, J = 6.5, Me); 0.83 (d, 
J = 7.1, Me). 13C-NMR (CD3OD): 178.8 (C=O); 125.2, 122.6 (C(4’), C(5’)); 124.8 
(C(2’)); 63.5 (CHN); 31.9 (CH); 17.9, 17.6 (2 Me); 7.4, 5.6 (2 imidazole Me). HR-EI-
MS: 213.1232 ([M+H]+, C10H17N2O3; calc. 213.1240).  
4. General Procedure for the Synthesis of Hydrazides 2. To a soln. of an 
imidazole-2-thione 4 (1 mmol) in CH2Cl2 (5 ml) was added methyl bromoacetate (1 
mmol). The mixture was stirred for 48 h at r.t., then, the solvent was evaporated under 
vacuum, and the residue was used immediately without further purification. The oily 
residue was dissolved in EtOH (5 ml) and NH2NH2·H2O (2 mmol) was added. The 
mixture was heated under reflux for 2 h, the solvent was evaporated under vacuum, and 
the residue was crystallized from MeOH.  
 2-[(1-Benzyl-4,5-dimethylimidazol-2-yl)sulfanyl]acetohydrazide (2a). Yield: 
0.225 g (88%). Colorless crystals. M.p. 127–129º (MeOH). IR (KBr): 3321s (NH), 
1671vs (C=O), 1420m, 722m. 1H-NMR (CDCl3): 9.88 (br. s, NH); 7.26–6.91 (m, 5 
arom. H); 4.99 (s, CH2N); 3.48 (s, CH2S); 2.10, 1.96 (2s, 2 Me). 13C-NMR (CDCl3): 
170.2 (C=O); 138.6 (C(2’)); 136.0, 134.6, 125.3 (1 arom. C, C(4’), C(5’)); 129.0, 127.9, 
126.2 (5 arom. CH); 47.9 (CH2N); 35.4 (CH2S); 12.7, 9.2 (2 Me). HR-EI-MS: 291.1275 
([M+H]+, C14H19N4OS; calc. 291.1280).  
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 2-[(1-Cyclohexyl-4,5-dimethylimidazol-2-yl)sulfanyl]acetohydrazide (2b). 
Yield: 0.212 g (75%). Colorless crystals. M.p. 117–119º (MeOH). IR (KBr): 3314s, 
3226s (br., NH), 1676vs (C=O), 1615vs, 1523m, 1413m, 1003m. 1H-NMR (CDCl3): 
10.0 (br. s, NH); 3.97–3.93 (m, CH); 3.63 (s, CH2S); 2.16, 2.11 (2s, 2 Me); 2.03–1.71 
(m, 7 cyclohexyl H); 1.39–1.18 (m, 3 cyclohexyl H). 13C-NMR (CDCl3): 170.5 (C=O); 
137.9 (C(2’)); 134.2, 124.6 (C(4’), C(5’)); 57.2 (CH); 35.2 (CH2S); 31.7, 26.2, 25.2 (5 
cyclohexyl CH2); 12.6, 10.6 (2 Me). HR-EI-MS: 283.1589 ([M+H]+, C13H23N4OS; calc. 
283.1588).  
 2-[(1-Benzyl-4,5-diphenylimidazol-2-yl)sulfanyl]acetohydrazide (2c). Yield: 
0.323 g (76%). Colorless crystals. M.p. 112–115º (MeOH). IR (KBr): 3329s, 3276s  
(NH), 1673vs (C=O), 1601vs, 1453m, 1436m, 701m. 1H-NMR (CDCl3): 9.96 (br. s, 
NH); 7.38–6.82 (m, 15 arom. H); 4.90 (s, CH2N); 3.67 (s, CH2N). 13C-NMR (CDCl3): 
170.2 (C=O); 142.3, 131.1, 129.2 (3 arom. C); 138.2, 133.5 (C(4’), C(5’)); 136.0 
(C(2’)); 131.0, 130.1, 129.1, 128.8, 128.6, 127.9, 126.8, 126.6, 126.4 (15 arom. CH); 
48.1 (CH2N); 34.6 (CH2S). HR-EI-MS: 415.1583 ([M+H]+, C24H23N4OS; calc. 
415.1588).  
5. General Procedure for the Synthesis of 1H-Imidazole-2-thiones 4. To a 
magnetically stirred soln. of 1H-imidazole N-oxide (1 mmol) in CH2Cl2 (1 ml), a soln. 
of 2,2,4,4-tetramethylcyclobutane-1,3-dithione [18][19] (0.6 mmol) in CH2Cl2 (1 ml) 
was added dropwise. The addition was complete after ca. 10 min, and stirring was 
continued for 24 h, while a little precipitate was formed. Then, the solvent was removed 
under reduced pressure, the resulting solid was washed with hexane, and filtered. The 
crude product was recrystallized from MeOH.  
Ethyl 1-Benzyl-5-methyl-2-thioxo-1H-imidazole-4-carboxylate (4d). Yield: 
0.146 g (53%). Colorless crystals. M.p. 205–207º (decomp., MeOH). IR (KBr): 1706vs 
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(C=O), 1417vs, 1335m, 721m. 1H-NMR ((D6)DMSO): 12.87 (br. s, NH);  7.35–7.21 (m, 
5 arom. H); 5.36 (s, CH2); 4.22 (q, J = 7.1, MeCH2O); 2.28 (s, Me); 1.26 (t, J = 7.1, 
MeCH2O). 13C-NMR ((D6)DMSO): 164.3 (C=S); 159.1 (C=O); 136.6, 115.8 (C(4), 
C(5)); 135.4 (1 arom. C); 129.1, 127.9, 127.2 (5 arom. CH); 60.9 (MeCH2O); 47.0 
(CH2); 14.5 (MeCH2O); 10.9 (Me). HR-ESI-MS: …………… ([M+H]+, C14H17N2O2S; 
calc. 227.1005). 
N-(2-Adamantylidenamino)-1-benzyl-5-methyl-2-thioxo-1H-imidazole-4-
carboxamide (4e). Yield: 0.345 g (88%). Colorless crystals. M.p. 284–286º (decomp., 
MeOH). IR (KBr): 3293s (NH), 3140s, 3063s, 1616vs (C=O), 1510m, 1496m, 1406m, 
1365m. 1H-NMR (D6)DMSO): 12.78 (br. s, NH); 9.99 (br. s, imidazol NH); 7.36–7.23 
(m, 5 arom. H); 5.34 (s, CH2); 3.32, 2.55 (2br. s, 2 adamantyl CH); 2.28 (br. s, Me); 
1.99–1.75 (m, 12 adamantyl H). 13C-NMR ((D6)DMSO): 162.5 (C=O); 155.5 (C=S); 
136.8 (C=N); 133.3, 117.9 (C(4), C(5)); 130.0 (1 arom. C); 129.1, 127.9, 127.3 (5 arom. 
CH); 46.9 (CH2); 39.1, 37.8, 36.3, 31.6, 27.6 (9 adamantyl C); 10.7 (Me). HR-ESI-MS: 
395.1895 ([M+H]+, C22H27N4O2S; calc. 395.1900). 
6. Synthesis of 1-Benzyl-2-[(2-hydrazino-2-oxoethyl)sulfanyl]-5-
methylimidazole-4-carboxyhydrazide (7). To a soln. of imidazole-2-thione 4d (267 mg, 
1 mmol) in CH2Cl2 (5 ml) was added methyl bromoacetate (153 mg, 1 mmol). The 
mixture was stirred for 48 h at r.t., the solvent was evaporated under vacuum, and the 
residue was used for the following reaction without further purification. The oily 
residue was dissolved in EtOH (5 ml) and NH2NH2.H2O (2 mmol) was added. The 
mixture was stirred for 16 h at r.t., the solvent was evaporated under vacuum, and the 
residue was crystallized from MeOH. Yield of 7: 0.293 g (88%). Colorless crystals. 
M.p. 194–198º (MeOH). IR (KBr): 3315vs (N−H), 3203m, 1664vs (C=O), 1612vs, 
1594m, 1495m, 734m. 1H-NMR (CDCl3): 9.26, 8.99 (2br. s, 2 NH); 7.36–7.05 (m, 5 
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arom. H); 5.15 (s, CH2N); 4.30 (br. s, 2 NH2); 3.73 (s, CH2S); 2.38 (s, Me). 13C-NMR 
(CDCl3): 167.3, 162.9 (2 C=O); 140.3, 131.0 (C(4), C(5)); 136.6 (C(2)); 133.9 (1 arom. 
C); 129.3, 128.1, 126.9 (5 arom. CH); 47.2 (CH2N); 35.1 (CH2S); 10.0 (Me). HR-EI-
MS: 335.1286 ([M+H]+, C14H19N6O2S; calc. 335.1285).  
7. General Procedure for the Synthesis of 8a–8f. To a stirred soln. of a 
hydrazide 1 (1 mmol) in MeOH (4 ml) at 20º, an equimolar quantity of the carbonyl 
component (bezaldehyde, adamantan-2-one, cyclohexanone) was added slowly. The 
mixture was stirred for 16 h at r.t., the soln. was concentrated, the resulting solid was 
treated with Et2O, filtered, and crystallized from MeOH.  
 1-Benzyl-N-(benzylidenamino)-5-methyl-3-oxido-1H-imidazole-4-
carboxamide (8a). Yield: 0.308 g (92%). Colorless crystals. M.p. 232–234° (decomp., 
MeOH). IR (KBr): 3086m, 1667vs (C=O), 1607vs, 1594m, 1558m, 1461m. 1H-NMR 
(CDCl3): 13.80 (br. s, NH); 8.20 (s, H–C=N); 7.79–7.77 (m, 2 arom. H; H–C(2)); 7.41–
7.15 (m, 8 arom. H); 5.07 (s, CH2); 2.67 (s, Me). 13C-NMR (CDCl3):  156.3 (C=O); 
149.0 (C=N); 134.1, 122.2 (C(4), C(5)); 133.0, 132.2 (2 arom. C); 130.3, 129.6, 129.3, 
128.6,  127.8, 127.3 (10 arom. CH); 125.3 (C(2)); 49.6 (CH2); 9.8 (Me). HR-ESI-MS: 
335.1503 ([M+H]+, C19H19N4O2; calc. 335.1503).  
 N-(Benzylidenamino)-1-cyclohexyl-5-methyl-3-oxido-1H-imidazole-4-
carboxamide (8b). Yield: 0.229 g (70%). Colorless crystals. M.p. 206–208º (decomp., 
MeOH). IR (KBr): 3109m, 1671vs (C=O), 1608vs, 1592m, 1417m, 1270m. 1H-NMR 
(CDCl3): 13.89 (br. s, NH); 8.21 (s, H–C=N); 7.85 (s, H–C(2)); 7.80–7.78 (m, 2 arom. 
H); 7.39–7.37 (m, 3 arom. H); 3.98–3.93 (m, CHN); 2.70 (s, Me); 2.09–1.96 (m, 4 
cyclohexyl H); 1.70–1.42 (m, 5 cyclohexyl H); 1.30–1.23 (m, 1 cyclohexyl H). 13C-
NMR (CDCl3): 156.5 (C=O); 148.8 (C=N); 134.2 (1 arom. C); 131.2, 121.4 (C(4), 
C(5)); 130.2, 128.6, 127.8 (5 arom. CH); 122.6 (C(2)); 55.7 (CH); 33.7, 25.4, 24.9 (5 
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cyclohexyl CH2); 9.6 (Me). HR-ESI-MS: 327.1816 ([M+H]+, C18H23N4O2; calc. 
327.1816).  
 N-(2-Adamantylidenamino)-1-benzyl-5-methyl-3-oxido-1H-imidazole-4-
carboxamide (8c). Yield: 0.302 g (80%). Colorless crystals. M.p. 260–262º (decomp., 
MeOH). IR (KBr): 3181m (NH), 3042m, 1682vs (C=O), 1602vs, 1547m, 1255m. 1H-
NMR (CDCl3): 13.35 (br. s, NH); 7.76 (s, H–C(2)); 7.41–7.38 (m, 3 arom. H); 7.13–
7.12 (m, 2 arom. H); 5.07 (s, CH2); 3.23, 2.87 (2br. s, 2 adamantyl CH); 2.64 (s, Me); 
2.05–1.80 (m, 12 adamantyl H). 13C-NMR (CDCl3): 168.5 (C=O); 156.1 (C=N); 133.1, 
122.7 (C(4), C(5)); 131.8 (1 arom. C); 129.6, 129.2, 127.1 (5 arom. CH); 125.0 (C(2)); 
49.5 (CH2); 39.4, 39.1, 37.9, 36.4, 32.8, 27.8 (9 adamantyl C); 9.8 (Me). HR-ESI-MS: 
379.2132 ([M+H]+, C22H27N4O2; calc. 379.2128).  
 N-(2-Adamantylidenamino)-1-cyclohexyl-5-methyl-3-oxido-1H-imidazole-4-
carboxamide (8d). Yield: 0.260 g (70%). Colorless crystals. M.p. 226–228º (decomp., 
MeOH). IR (KBr): 3104w (NH), 1679vs (C=O), 1596vs, 1416m. 1H-NMR (CDCl3): 
13.47 (br. s, NH); 7.77 (s, H–C(2)); 3.96–3.90 (m, CHN); 3.22, 2.85 (2br. s, 2 
adamantyl CH); 2.68 (s, Me); 2.09–2.02 (m, 2 cyclohexyl H); 2.01–1.82 (m, 12 
adamantyl H, 1 cyclohexyl H); 1.81–1.75 (m, 2 cyclohexyl H); 1.57–1.38 (m, 4 
cyclohexyl H); 1.30-1.21 (m, 1 cyclohexyl H). 13C-NMR (CDCl3): 168.1 (C=O); 156.5 
(C=N); 130.7, 121.9 (C(4), C(5)); 122.4 (C(2)); 55.6 (CHN); 39.4, 39.3, 39.1, 37.9, 
36.4, 33.7, 32.7, 27.8, 25.4, 24.8 (9 adamantyl C, 5 cyclohexyl C); 9.5 (Me). HR-ESI-
MS: 371.2441 ([M+H]+, C21H31N4O2; calc. 371.2442).  
 1-Benzyl-N-(cyclohexylidenamino)-5-methyl-3-oxido-1H-imidazole-4-
carboxamide (8e). Yield: 0.320 g (98%). Colorless crystals. M.p. 220–222º (decomp., 
MeOH). IR (KBr): 3081s, 2930s, 1667vs (C=O), 1602vs, 1559m, 1452m. 1H-NMR 
(CDCl3): 13.46 (br. s, NH); 7.77 (s, H–C(2)); 7.40–7.38 (m, 3 arom. H); 7.13–7.11 (m, 2 
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arom. H); 5.06 (s, CH2); 2.63 (s, Me); 2.63–2.43 (m, 4 cyclohexyl H); 1.73–1.67 (m, 4 
cyclohexyl H); 1.64–1.60 (m, 2 cyclohexyl H). 13C-NMR (CDCl3): 161.8 (C=O); 156.1 
(C=N); 133.1, 122.6 (C(4), C(5)); 131.8 (1 arom. C); 129.5, 129.2, 127.1 (5 arom. CH); 
125.1 (C(2)); 49.5 (CH2); 35.4, 28.1, 27.0, 26.1, 25.7 (5 cyclohexyl C); 9.8 (Me). HR-
ESI-MS: 327.1814 ([M+H]+, C18H23N4O2; calc. 327.1816).  
 1-Cyclohexyl-N-(cyclohexylidenamino)-5-methyl-3-oxido-1H-imidazole-4-
carboxamide (8f). Yield: 0.239 g (75%). Colorless crystals. M.p. 218–220º (decomp., 
MeOH). IR (KBr): 3084m, 2931vs, 1685vs (C=O), 1596vs, 1538m, 1416m, 1261m. 1H-
NMR (CDCl3): 13.47 (br. s, NH); 7.82 (s, H–C(2)); 3.97–3.91 (m, CHN); 2.68 (s, Me); 
2.46–2.43 (m, 4 cyclohexyl H); 2.07–2.05 (m, 2 cyclohexyl H); 1.97–1.95 (m, 2 
cyclohexyl H); 1.78–1.66 (m, 5 cyclohexyl H); 1.65–1.60 (m, 2 cyclohexyl H); 1.58–
1.39 (m, 4 cyclohexyl H); 1.30–1.21 (m, 1 cyclohexyl H). 13C-NMR (CDCl3): 161.5 
(C=O); 156.3 (C=N); 130.8, 121.8 (C(4), C(5)); 122.5 (C(2)); 55.6 (CHN); 35.5, 33.7, 
28.1, 27.0, 26.1, 25.7, 25.4, 24.8 (10 cyclohexyl C); 9.54 (Me). HR-ESI-MS: 319.2129 
([M+H]+, C17H27N4O2; calc. 319.2128).  
8. General Procedure for the Synthesis of 8g,h and 9a–g: A soln. of hydrazide 1 
or 2 (1 mmol) in EtOH (4 ml) and an equimolar amount of the carbonyl component (4-
methoxy-, 4-dimethylamino-, 4-methylsulfanylbenzaldehyde, cyclohexanone) and a 
catalytic amount of AcOH was heated to reflux for 4 h. After cooling to r.t., the solvent 
was evaporated under reduced pressure, the residue was dissolved in CH2Cl2 and, after 
addition of NaHCO3, stirred for 0.5 h. The mixture was filtered, the solvent evaporated 
under reduced pressure, and the residue was purified by crystallization from MeOH.  
 1-Benzyl-5-methyl-3-oxido-N-(1-phenylethylidenamino)-1H-imidazole-4-
carboxamide (8g). Yield: 0.261 g (76%). Colorless crystals. M.p. 222–226º (decomp., 
MeOH). IR (KBr): 3061m, 2914m, 1678vs (C=O), 1602vs, 1546m, 1269m, 705m. 1H-
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NMR (CDCl3): 13.71 (br. s, NH); 7.90–7.88 (m, 2 arom. H); 7.82 (s, H–C(2)); 7.42–
7.36 (m, 6 arom. H); 7.16–7.14 (m, 2 arom. H); 5.09 (s, CH2); 2.67 (s, imidazole Me); 
2.39 (s, MeC=N). 13C-NMR (CDCl3): 156.2 (C=O); 153.0 (C=N); 138.1, 132.1 (2 arom. 
C); 133.0, 122.6 (C(4), C(5)); 129.6, 129.4, 129.3, 128.2, 127.2, 126.8 (12 arom. C); 
125.2 (C(2)); 49.6 (CH2); 14.5 (MeC=N); 9.8 (imidazole Me). HR-ESI-MS: 349.1664 
([M+H]+, C20H21N4O2; calc. 349.1659).  
 1-Cyclohexyl-5-methyl-3-oxido-N-(1-phenylethylidenamino)-1H-imidazole-4-
carboxamide (8h). Yield: 0.238 g (70%). Colorless crystals. M.p. 264–268º (decomp., 
MeOH). IR (KBr): 3080m, 2937s 1675vs (C=O), 1601vs, 1553m, 1417m, 1273m. 1H-
NMR (CDCl3): 13.67 (br. s, NH); 7.94–7.92 (m, 2 arom. H, H–C(2)); 7.41–7.39 (m, 3 
arom. H); 4.03–3.98 (m, CHN); 2.75 (s, imidazole Me); 2.43 (s, MeC=N); 2.14–2.00 (m, 
4 cyclohexyl H); 1.64–1.45 (m, 4 cyclohexyl H); 1.34–1.25 (m, 2 cyclohexyl H). 13C-
NMR (CDCl3): 156.2 (C=O); 152.9 (C=N); 138.1 (1 arom. C); 131.2, 121.8 (C(4), 
C(5)); 129.4, 128.2, 126.8 (5 arom. CH); 122.8 (C(2)); 55.8 (CHN); 33.7, 25.4, 24.8 (5 
cyclohexyl C); 14.5 (MeC=N); 9.6 (Me). HR-ESI-MS: 341.1975 ([M+H]+, C19H25N4O2; 
calc. 341.1972).  
 2-(1-Benzyl-4,5-dimethylimidazol-2-yl)sulfanyl-N-[(4-methoxyphenyl) 
methylenamino]acetamide (9a). Yield: 0.237 g (57%). Colorless crystals. M.p. 130–
132º (MeOH). IR (KBr): 3186m (br.), 3067m (br.), 1664vs (C=O), 1606vs, 1407m, 
1245m. 1H-NMR (CDCl3): 12.82 (br. s, NH); 8.12 (s, H–C=N); 7.72–6.89 (m, 9 arom. 
H); 5.08 (s, CH2N); 3.84 (s, MeO); 3.61 (s, CH2S); 2.24, 2.05 (2s, 2 imidazole Me). 13C-
NMR (CDCl3): 166.0 (C=O); 161.4 (C=N); 147.8 (arom. C–O); 139.3 (C(2’)); 135.9, 
125.5 (C(4’), C(5’)); 134.1(1 arom. C); 129.3, 129.0, 128.0, 126.6, 126.3, 114.1 (10 
arom. C); 55.4 (MeO); 48.1 (CH2N); 36.3 (CH2S); 12.7, 9.2 (2 imidazole Me). HR-EI-
MS: 409.1701 ([M+H]+, C22H24N4O2S; calc. 409.1694).  
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 2-(1-Benzyl-4,5-dimethylimidazol-2-yl)sulfanyl-N-[(4-dimethylaminophenyl) 
methylenamino]acetamide (9b). Yield: 0.337 (80%). Colorless crystals. M.p. 75–79º 
(MeOH). IR (KBr): 3203m (br.), 3023m (br.), 2917s (br.), 1679vs (C=O), 1608vs, 
1525m, 1360m, 1180m. 1H-NMR (CDCl3): 12.52 (br. s, NH); 8.05 (s, H–C=N); 7.64–
6.66 (m, 9 arom. H); 5.07 (s, CH2N); 3.60 (s, CH2S); 3.01 (s, Me2N); 2.23, 2.04 (2s, 2 
imidazole Me). 13C-NMR (CDCl3): 165.6 (C=O); 151.9 (C=N); 148.8 (arom. C–N); 
139.3 (C(2’)); 135.9 (1 arom. C); 134.2, 121.6 (C(4’), C(5’)); 129.2, 129.0, 127.9, 
126.32, 126.29, 111.6 (10 arom. C); 48.0 (CH2N); 40.2 (Me2N); 36.3 (CH2S); 12.7, 9.2 
(2 imidazole Me). HR-EI-MS: 422.2009 ([M+H]+, C23H28N5OS; calc. 422.2010).  
 2-(1-Benzyl-4,5-dimethylimidazol-2-yl)sulfanyl-N-(cyclohexylidenamino) 
acetamide (9c). Yield: 0.322 g (87%). Colorless crystals. M.p. 124–130º (MeOH). IR 
(KBr): 3207m (br., NH), 3061m (br.), 1667vs (C=O), 1406m, 718m. 1H-NMR (CDCl3): 
11.81 (br. s, NH); 7.33–6.99 (m, 5 arom. H); 5.04 (s, CH2N); 3.61 (s, CH2S); 2.54–2.42 
(m, 4 cyclohexyl H); 2.12, 2.03 (2s, 2 imidazole Me); 1.75–1.61 (m, 6 cyclohexyl H). 
13C-NMR (CDCl3): 166.7 (C=O); 160.9 (C=N); 140.0 (C(2’)); 135.9 (1 arom. C); 134.1, 
125.2 (C(4’), C(5’)); 129.0, 127.9, 126.2 (5 arom. CH); 48.0 (CH2N); 36.2 (CH2S); 
35.4, 28.3, 27.0, 26.1, 25.7 (5 cyclohexyl CH2); 12.6, 9.2 (2 imidazole Me). HR-EI-MS: 
371.1879 ([M+H]+, C20H27N4OS; calc. 371.1901).  
 2-(1-Cyclohexyl-4,5-dimethylimidazol-2-yl)sulfanyl-N-[(4-methylsulfanyl-
phenyl)methylenamino]acetamide (9d). Yield: 0.152 g (37%). Colorless crystals. M.p. 
76–78º (MeOH). IR (KBr): 3296m, (br., NH), 3058m, 1667vs (C=O), 1596vs, 1505m, 
1363m. 1H-NMR (CDCl3): 13.11 (br. s, NH); 8.05 (s, H–C=N); 7.66–7.21 (m, 4 arom. 
H); 3.99–3.95 (m, CHN); 3.70 (s, CH2S); 2.49 (s, MeS); 2.19, 2.18 (2s, 2 imidazole 
Me); 2.05–1.72 (m, 7 cyclohexyl H); 1.42–1.18 (m, 3 cyclohexyl H). 13C-NMR 
(CDCl3): 166.5 (C=O); 147.2 (C=N); 141.6 (C(2’)); 138.6, 130.6 (C(4’), C(5’)); 134.9 
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(1 arom. C);  128.0, 125.8, 124.8 (5 arom. C); 57.4 (CHN); 36.2 (CH2S); 31.7, 26.2, 
25.2 (5 cyclohexyl CH2); 15.2 (MeS); 12.7, 10.5 (2 imidazole Me). HR-EI-MS: 
417.1767 ([M+H]+, C21H29N4OS2; calc. 417.1778).  
 2-(1-Cyclohexyl-4,5-dimethylimidazol-2-yl)sulfanyl-N-[(4-methoxyphenyl) 
methylenamino]acetamide (9e). Yield: 0.288 g (72%). Colorless crystals. M.p. 96–102º 
(MeOH). IR (KBr): 3203m (br., NH), 2917s (br.), 1664vs (C=O), 1607vs, 1512m, 
1418m, 1307m, 1250m. 1H-NMR (CDCl3): 12.96 (br. s, NH); 8.05 (s, H–C=N); 7.69–
6.86 (m, 4 arom. H); 3.99–3.96 (m, CHN); 3.83 (s, MeO); 3.70 (s, CH2S); 2.19, 2.18 (2s, 
2 imidazole Me); 2.05–1.74 (m, 7 cyclohexyl H); 1.42–1.18 (m, 3 cyclohexyl H). 13C-
NMR (CDCl3): 166.4 (C=O); 147.6 (C=N); 147.6 (1 arom. C–O); 141.6, 126.7 (C(4’), 
C(5’)); 138.6 (C(2’)); 129.3, 124.7, 114.1 (5 arom. C); 57.4 (CHN); 55.3 (MeO); 36.2 
(CH2S); 31.7, 26.2, 25.2 (5 cyclohexyl CH2); 12.6, 10.5 (2 imidazole Me). HR-EI-MS: 
401.1986 ([M+H]+, C21H29N4O2S; calc. 401.2007).  
 2-(1-Benzyl-4,5-diphenylimidazol-2-yl)sulfanyl-N-[(4-methylsulfanylphenyl) 
methylenamino]acetamide (9f). Yield: 0.390 g (71%). Colorless crystals. M.p. 154–156º 
(MeOH). IR (KBr): 3296m (br., NH), 3058m (br.), 1683vs (C=O), 1596vs, 1433m, 
702m. 1H-NMR (CDCl3): 12.90 (br. s, NH); 7.87 (s, H–C=N); 7.50–6.92 (m, 19 arom. 
H); 5.01 (s, CH2N); 3.83 (s, CH2S); 2.47 (s, MeS). 13C-NMR (CDCl3): 165.9 (C=O); 
148.1 (C=N); 143.1, 141.7, 131.2, 129.7  (4 arom. C); 137.9, 133.6 (C(4’), C(5’)); 135.8 
(C(2’)); 130.9, 130.4, 129.3, 129.2, 128.9, 128.5, 128.01, 127.98, 127.1, 126.6, 126.5, 
125.8 (1 arom. C, 19 arom. CH); 48.3 (CH2N); 35.6 (CH2S); 15.2 (MeS). HR-EI-MS: 
549.1770 ([M+H]+, C32H29N4OS2; calc. 549.1778).  
 2-(1-Benzyl-4,5-diphenylimidazol-2-yl)sulfanyl-N-(cyclohexylidenamino) 
acetamide (9g). Yield: 0.329 g (67%). Colorless crystals. M.p. 166–168º (MeOH). IR 
(KBr): 3321s (br., NH), 3026m,1679vs (C=O), 1602vs, 1453m, 1433m, 701m. 1H-NMR 
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(CDCl3): 11.38 (br. s, NH); 7.36–6.92 (m, 15 arom. H); 4.97 (s, CH2N); 3.93 (s, CH2S); 
2.34–1.93 (m, 4 cyclohexyl H); 1.62–1.03 (6 cyclohexyl H). 13C-NMR (CDCl3): 166.3 
(C=O); 161.4 (C=N); 143.6, 131.2 (C(4’), C(5’)); 135.7 (C(2’)); 131.0, 130.9, 129.7, 
129.0, 128.8, 128.3, 128.2, 127.9, 126.9, 126.7, 126.6 (3 arom. C, 15 arom. CH); 48.3 
(CH2N); 35.3 (CH2S); 34.6, 27.8, 26.7, 25.4, 25.3 (5 cyclohexyl CH2). HR-EI-MS: 
495.2207 ([M+H]+, C30H31N4OS; calc. 495.2214).  
9. Synthesis of 1-{[(1-Benzyl-5-methyl-3-oxidoimidazolium-4-yl)-4-
carbonyl]amino}-3-methylthiourea (10): A mixture of 1b (247 mg, 1 mmol) and methyl 
isothiocyanate (80 mg, 1.1 mmol) in EtOH (5 ml) was heated to reflux for 2 h. The 
formed product 10 was then filtered off, washed with Et2O, and crystallized from 
MeOH. Yield: 0.257 g (90%). Colorless crystals. M.p. 224–228º (MeOH). IR (KBr): 
3271vs (NH), 3097s (br.), 1682vs (C=O), 1599vs, 1557m, 740m. 1H-NMR 
((D6)DMSO): 12.39, 9.34 (2br. s, 2 NH); 8.71 (s, H–C(2)); 8.00 (br. s, NH); 7.42–7.24 
(m, 5 arom. H); 5.25 (s, CH2N); 2.85 (d, J = 4.3, Me); 2.43 (s, Me). 13C-NMR 
((D6)DMSO): 182.6 (C=O); 135.8 (C=S); 131.3, 121.3 (C(4’), C(5’)); 130.2 (1 arom. 
C); 129.5, 128.7, 127.7 (5 arom. CH); 126.8 (C(2’)); 48.7 (CH2N); 31.4 (MeN); 9.8 
(Me). HR-ESI-MS: 320.1174 ([M+H]+, C14H19N5O2S; calc. 320.1103).  
10. Synthesis of 1-Benzyl-4-(4,5-dihydro-4-methyl-5-thioxo-1H-1,2,4-triazol-3-
yl)-5-methyl-1H-imidazole 3-Oxide (11). A mixture of 10 (320 mg, 1 mmol) and a 2% 
aq. soln. of NaOH (5 ml) was heated to reflux for 2 h. Then, the soln. was neutralized 
with AcOH and the formed precipitate was filtered off and crystallized from MeOH. 
Yield of 11: 0.217 g (72%). Colorless crystals. M.p. 244–248º (MeOH). IR (KBr): 
3161s (NH), 1564m, 1457m, 1341m, 698m. 1H-NMR ((D6)DMSO): 14.02 (br. s, NH); 
8.58 (s, H–C(2)); 7.43–7.29 (m, 5 arom. H); 5.23 (s, CH2N); 3.50 (s, MeN); 2.14 (s, 
Me). 13C-NMR ((D6)DMSO): 168.1 (C=S); 142.6 (triazol C(3)); 136.1, 118.0 
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(imidazole C(4), C(5)); 129.5, 128.63, 127.8 (5 arom. CH); 128.60 (1 arom. C); 126.5 
(imidazole C(2)); 49.2 (CH2N); 31.7 (MeN); 9.4 (Me). HR-ESI-MS: 302.1068 ([M+H]+, 
C14H16N5OS; calc. 302.0997).  
11. Synthesis of 1-Benzyl-5-methyl-4-(5-methylamino-1,3,4-thiadiazol-2-yl)-1H-
imidazole 3-Oxide (12). A soln. of 10 ((320 mg, 1 mmol) in conc. H2SO4 (5 ml) was 
kept at r.t. for 1 d. After neutralization of the soln. with diluted NH4OH, the solid 
product was filtered off, dried, and crystallized from MeOH. Yield of 12: 0.162 g 
(54%). Yellowish crystals. M.p. 214–216º (decomp., MeOH). IR (KBr): 3201m (br.), 
3127s, 2963s (br.), 1517m, 1261m, 1096m, 1031m, 800m. 1H-NMR ((D6)DMSO): 8.57 
(s, H–C(2)); 7.52 (br. s, NH); 7.41–7.26 (m, 5 arom. H); 5.24 (s, CH2N); 2.89 (d, J = 
4.8, MeN); 2.49 (s, Me). 13C-NMR ((D6)DMSO): 169.9, 144.7 (thiadiazol C(2), C(5)); 
136.3, 123.0 (imidazole C(4), C(5)); 129.4, 128.5, 127.6 (5 arom. CH); 125.3 
(imidazole C(2)); 124.0 (1 arom. C); 48.9 (CH2N); 31.7 (MeN); 10.1 (Me). HR-ESI-
MS: 302.1068 ([M+H]+, C14H16N5OS; calc. 302.1076).  
12. X-Ray Crystal Structure Determination of 1b (Table and Figure)4). All 
measurements were made on an Agilent Technologies SuperNova area-detector 
diffractometer [20] using MoKα radiation (λ = 0.71073 Å) from a micro-focus X-ray 
source and an Oxford Instruments Cryojet XL cooler. Data reduction was performed 
with CrysAlisPro [20].  The intensities were corrected for Lorentz and polarization 
effects, and an empirical absorption correction using spherical harmonics [20] was 
applied.  The space group was determined from packing considerations, a statistical 
                                                          
4) CCDC-838434 contains the supplementary crystallographic data for this paper. These 
data can be obtained free of charge from the Cambridge Crystallographic Data Centre, 
via www.ccdc.cam.ac.uk/data_request/cif. 
 
 22 
analysis of intensity distribution, and the successful solution and refinement of the 
structure.  Equivalent reflections were merged.  The data collection and refinement 
parameters are given in the Table.  A view of the molecule is shown in the Figure. The 
structure was solved by direct methods using SHELXS97 [21], which revealed the 
positions of all non-H-atoms.  The non-H-atoms were refined anisotropically.  The 
hydrazide H-atoms were placed in the positions indicated by a difference electron 
density map and their positions were allowed to refine together with individual isotropic 
displacement parameters.  All remaining H-atoms were placed in geometrically 
calculated positions and refined by using a riding model where each H-atom was 
assigned a fixed isotropic displacement parameter with a value equal to 1.2Ueq of its 
parent C-atom (1.5Ueq for the Me group).  The refinement of the structure was carried 
out on F2 by using full-matrix least-squares procedures, which minimized the function 
Σw(Fo2 – Fc2)2.  The weighting scheme was based on counting statistics and included a 
factor to downweight the intense reflections. A correction for secondary extinction was 
applied. Neutral atom scattering factors for non-H-atoms were taken from [22a], and the 
scattering factors for H-atoms were taken from [23].  Anomalous dispersion effects 
were included in Fc [24]; the values for f' and f" were those of [22b].  The values of the 
mass attenuation coefficients are those of [22c].  The SHELXL97 program [25] was used 
for all calculations. 
 
Table. Crystallographic Data for Compound 1b 
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Table.  Crystallographic Data for Compound 1b 
__________________________________________________________________________________ 
  
Crystallized from MeOH  
Empirical formula C12H14N4O2  
Formula weight [g mol-1] 246.27  
Crystal color, habit pale-yellow, prism  
Crystal dimensions [mm] 0.28 × 0.30 × 0.30  
Temperature [K] 160(1)  
Crystal system triclinic  
Space group P
_
,1  
Z 2  
Reflections for cell determination 7053  
2θ range for cell determination [°] 5 – 59  
Unit cell parameters a [Å] 6.8168(2)  
 b [Å] 7.6666(2)  
 c [Å] 11.7286(4)  
 α [°] 97.379(3)  
 β [°] 93.255(3)  
 γ  [°] 101.516(3)  
 V [Å3] 593.49(3)  
Dx [g cm-3] 1.378  
µ(MoKα) [mm-1] 0.0977  
Scan type ω  
2θ(max) [°] 58.5  
Transmission factors (min; max) 0.855; 1.000  
Total reflections measured 10252  
Symmetry independent reflections 2815  
Reflections with I > 2σ(I) 2618  
Reflections used in refinement 2815  
Parameters refined 177  
Final R(F) [I > 2σ(I) reflections] 0.0412  
 wR(F2) (all data) 0.1054  
Weights: w = [σ2(Fo2) + (0.0466P)2 + 0.2729P]-1 where P = (Fo2 + 2Fc2)/3  
Goodness of fit 1.038  
Secondary extinction coefficient 0.013(4)  
Final ∆max/σ 0.001  
∆ρ (max; min) [e Å-3] 0.33; -0.41  
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Scheme 7 
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